MERISLON Tablet

គុណភាពព្យាបាល
ងងឹតមុខ វិលមុខ។
កំរិតនិងរបៀបប្រើ
មនុស្សពេញវ័យ៖ លេបម្ដងពី 6mg ទៅ 12mg 3ដងក្នុង1ថ្ងៃ ក្រោយពេលស្រស់ស្រូបអាហារ។ កំរិតប្រើតំរូវតាមអាយុនិងរោគសញ្ញានៃអ្នកជម្ងឺ។

Vertigo and dizziness associated with the following diseases:

- Meniere’s disease

- Meniere’s syndrome

- Peripheral vertigo

Dosage and administration

Adult: 6-12mg, 3 times daily after meals.

The dosage may be adjusted depending on the patient’s age and symptoms.

ហាមប្រើចំពោះអ្នកជម្ងឺមានប្រវត្តិងាយប្រតិកម្មជាមួយសារធាតុផ្សំនៃឱសថនេះ។

ផលរំខានខ្លះៗ
ចង្អោរ ក្អួត កន្ទួលក្រហមលើស្បែក។

Side effects
Adverse reactions were reported in 26 of 2.254 patients (1.15%). (Post marketing clinical investigation).
- Gastrointestinal: Nausea/vomiting (5% > ≥0.1%)
- Hypersensitivity: Rash (5% > ≥0.1%)

ស្ត្រីមានផ្ទៃពោះ ស្ត្រីបំបៅកូន និងក្មេង ប្រើតែក្នុងករណីចាំបាច់ប៉ុណ្ណោះ ឬ ត្រូវពិគ្រោះជាមួយគ្រូពេទ្យមុនប្រើឱសថនេះ។

MERISLON should only be used in pregnant women or women suspected of being pregnant, if the expected therapeutic benefits are evaluated to outweigh the possible risk of treatment.

(The safety of MERISLON in pregnant women has not been established)

ការប្រុងប្រយ័ត្ន ចំពោះ៖
- អ្នកជម្ងឺមានប្រវត្តិដំបៅក្រពះ ឬ ដំបៅក្រពះកំពុងធ្វើទុក្ខព្រោះឱសថនេះអាចបណ្ដាលអោយក្រពះបញ្ចេញជាតិអាស៊ីតច្រើន។
- អ្នកជម្ងឺហឺត
- Pheochromocytoma ឱសថនេះអាចបណ្ដាលអោយអ្នកជម្ងឺមានសម្ពាធឈាមឡើង
- ស្ត្រីមានផ្ទៃពោះ ស្ត្រីបំបៅកូន និងក្មេង ប្រើតែក្នុងករណីចាំបាច់ប៉ុណ្ណោះ ឬ ត្រូវពិគ្រោះជាមួយគ្រូពេទ្យមុនប្រើឱសថនេះ
- ចំពោះមនុស្សចាស់ត្រូវបន្ថយកំរិតប្រើ។

1. Careful administration

(1) Patients with a history of peptic ulcer or with an active peptic ulcer

(2) Patients with bronchial asthma

(3) Patients with pheochromocytoma

2. Use in the Elderly

Since the elderly often have a physiological hypofunction, it is advisable to take measures, such as reduction in dosage under careful supervision.

3. Pediatric Use

The safety in children has not been established (insufficient clinical experience).

MERISLON dilates precapillary sphincters thus increasing the blood flow in the inner ear. It controls the permeability of capillaries in the inner ear, thereby removing endolymphatic hydrops. It also improves cerebral circulation, increasing blood flow in the internal carotid artery. MERISLON is clinically useful for the relief of vertigo and dizziness.

1. Improvement of circulatory disturbances in the inner ear

In the inner ear of the guinea pig with experimentally induced microcirculatory disturbances, the blood flow increases to 148% of the control level within 30min after the intraperitoneal injection of betahistine mesilate. This effect is specific for pathological conditions.

2. Increase of blood flow in the scala media of guinea pigs with endolymphatic hydrops

When betahistine mesilate was administered to guinea pigs with endolymphatic hydrops, it produced a significant increase in blood flow in the scala media. The blood flow increased significantly from 5.5mL/min/100g to 8.1mL/min/100g.It is considered that the increase in blood flow is due to relaxation of smooth muscle of the cochlear radial arteria.

3. Improvement of intracerebral blood flow

In the experiment in rhesus monkeys betahistine mesilate after intravenous administration increases blood flow in the cerebral and cerebellar tissues from 70.4-81.4 mL/100g/min and 73.2-84.0 mL/100g/min, respectively.